Global Health cash flow

Latest FY26

Cash from operations: ₹714cr+14.5% on FY25
Capital spending: ₹838cr+62.3% on FY25
Free cash flow: −₹124cr₹107 cr in FY25
Cash from financing: ₹248cr−₹97.2 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	223	194	173	150
	—	79.1	65.3	73.9	77.9
	—	−85.9	−70.3	−59.7	−35.5
	—	38.3	0.0	0.2	0.7
	—	2.6	−0.4	1.7	1.2
	—	−53.2	18.3	5.7	70.7
	—	0.0	2.3	26.8	4.3
	—	−11.8	−0.3	−6.5	−7.0
	—	−130	−94.9	−48.4	−21.5
	—	53.6	12.6	1.8	60.4
	—	0.0	0.0	−5.7	0.2
	—	0.0	14.5	0.0	0.0
Cash from operating activities
	720	715	647	627	449
	—	115	141	162	301
	—	830	788	790	751
	—	4.0	0.0	0.0	0.0
	—	119	164	177	106
	—	714	624	612	645
Cash from investing activities
	—	838	517	279	236
	—	0.8	3.0	1.4	0.8
	—	0.0	131	0.0	0.0
	—	0.0	2.7	0.0	0.0
	—	77.6	67.2	58.9	34.5
	—	−305	−141	−223	−142
	—	−1,065	−721	−441	−342
Cash from financing activities
	—	0.0	0.0	0.0	479
	—	0.0	1.3	0.0	0.0
	—	369	149	136	39.1
	—	12.1	183	582	66.6
	—	46.7	10.6	11.3	13.0
	—	38.8	53.7	56.7	92.3
	—	13.4	0.0	0.0	0.0
	—	−9.8	0.0	0.0	0.0
	—	248	−97.2	−514	346
	—	−103	−194	−343	648
	—	−103	−194	−343	648
	—	—	230	425	767
Reference items
	979	919	877	799	612
	20.9%	20.8%	23.8%	24.4%	22.7%
	−124	−124	107	334	409
	—	700	−37.9	−146	—
	−₹4.61	−₹4.61	₹3.99	₹12.41	₹15.20
	—	1.29×	1.30×	1.28×	1.98×
	—	119	164	177	106
	—	38.8	53.7	56.7	92.3

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MEDANTA₹1,299.70

Global Health Ltd.

· Pharma & Health

₹ CrorePeersMAXHEALTH APOLLOHOSP FORTIS GLAXO ANTHEM AJANTPHARM IPCALAB ABBOTINDIAMcap ₹34,922 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	149.9	172.7	193.7	222.5	—
+ Finance Costs	77.9	73.9	65.3	79.1	—
+ Interest Income	-35.5	-59.7	-70.3	-85.9	—
+ Share-based Payments	0.7	0.2	0.0	38.3	—
+ Unrealised FX (Gain) / Loss	1.2	1.7	-0.4	2.6	—
+ Other Non-cash Items	70.7	5.7	18.3	-53.2	—
+ Other Reconciling Items	4.3	26.8	2.3	0.0	—
Changes in Working Capital
+ Inventories	-7.0	-6.5	-0.3	-11.8	—
+ Trade Receivables — Current	-21.5	-48.4	-94.9	-130.3	—
+ Trade Payables — Current	60.4	1.8	12.6	53.6	—
+ Other Non-current Liabilities	0.2	-5.7	0.0	0.0	—
+ Provisions — Non-current	0.0	0.0	14.5	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	449.3	627.1	647.3	715.0	720.1
+ Total Adjustments (incl. Working Capital)	301.4	162.5	140.7	114.8	—
Cash from Operations (pre-tax)	750.7	789.5	788.0	829.8	—
+ Other Inflows / (Outflows) — Operating	0.0	0.0	0.0	4.0	—
+ Income Taxes Paid	106.1	177.5	164.2	119.4	—
Cash from Operating Activities	644.5	612.1	623.8	714.4	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	236.0	278.6	516.5	838.2	—
+ Disp of Fixed Assets	0.8	1.4	3.0	0.8	—
+ Acq of Other Long-term Assets	0.0	0.0	131.4	0.0	—
+ Purchase of Investments (Equity / Debt)	0.0	0.0	2.7	0.0	—
+ Interest Received — Investing	34.5	58.9	67.2	77.6	—
+ Other Inflows / (Outflows) — Investing	-141.6	-222.6	-140.5	-305.3	—
Cash from Investing Activities	-342.3	-440.8	-720.9	-1,065.1	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	478.5	0.0	0.0	0.0	—
+ Proceeds from Other Equity Instruments	0.0	0.0	1.3	0.0	—
+ Proceeds from Borrowings	39.1	136.3	149.2	368.7	—
+ Repayment of Borrowings	66.6	582.2	183.4	12.1	—
+ Payment of Lease Liabilities	13.0	11.3	10.6	46.7	—
+ Interest Paid	92.3	56.7	53.7	38.8	—
+ Dividends Paid	0.0	0.0	0.0	13.4	—
+ Other Inflows / (Outflows) — Financing	0.0	0.0	0.0	-9.8	—
Cash from Financing Activities	345.6	-513.9	-97.2	247.9	—
Net Changes in Cash (pre-FX)	647.8	-342.6	-194.4	-102.9	—
Net Changes in Cash	647.8	-342.6	-194.4	-102.9	—
Closing Cash	767.2	424.6	230.2	—	—
Reference Items
EBITDA	612.2	799.1	877.1	919.1	978.8
EBITDA Margin %	22.72	24.40	23.75	20.84	20.90
Free Cash Flow (CFO − Capex)	408.5	333.5	107.2	-123.8	-123.8
Free Cash Flow to Equity	—	-146.1	-37.9	699.6	—
Free Cash Flow per Basic Share	15.20	12.41	3.99	-4.61	-4.61
Cash Flow to Net Income	1.98	1.28	1.30	1.29	—
Cash Paid for Taxes	106.1	177.5	164.2	119.4	—
Cash Paid for Interest	92.3	56.7	53.7	38.8	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.